{"product_id":"hemovigilance-9780470655276","title":"Hemovigilance","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e* Hemovigilance is a quality process which aims to improve quality and increase safety of blood transfusion, by surveying all activities of the blood transfusion chain, from donors to recipients.\u003c\/p\u003e \u003cp\u003eHemovigilance programmes have now been in existence for over 15 years, but many countries and centers are still at the development stage. This valuable resource brings together the main elements of such programmes and shows the different types of models available. A general introduction includes Chapters on hemovigilance as a quality tool for transfusion as well as concepts of and models for hemovigilance. The core of the book describes how Hemovigilance systems have been set up and how they work in hospitals, blood establishments, and at a national level. These Chapters are written according to a structured template: products and processes, documentation of jobs, monitoring and assessment, implementation and evaluation of measures for improvement, education and training. Chapters on\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003e“This is a thoroughly fascinating read and will make you eager to implement or enhance your current hemovigilance efforts. I recommend it.”  (\u003ci\u003eDoody’s\u003c\/i\u003e, 26 April 2013)\u003c\/p\u003e \u003cp\u003e \u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eList of Contributors, viii  \u003cp\u003eForeword, xii\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 1 General Introduction\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction, 3\u003cbr\u003e \u003ci\u003eRen´e R.P. de Vries\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 Hemovigilance: A Quality Tool for the Blood Transfusion Chain, 5\u003cbr\u003e \u003ci\u003eRen´e R.P. de Vries\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 Concepts and Models, 12\u003cbr\u003e \u003ci\u003eRen´e R.P. de Vries and Jean-Claude Faber\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 2 Hemovigilance of the Blood Transfusion Chain (Blood Establishment and Hospital)\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eSection 2.1: Setting up a Hemovigilance System\u003c\/p\u003e \u003cp\u003e4 Setting Up or Consolidating a System for Donor Hemovigilance at the Level of a Blood Establishment, 21\u003cbr\u003e \u003ci\u003eJohanna Wiersum-Osselton, Wim de Kort, Tanneke Marijt-van der Kreek, and Jeroen de Wit\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 Preparation of Blood Components, 36\u003cbr\u003e \u003ci\u003eTomislav Vuk\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 Establishment of Hemovigilance for the Testing, Storage, Distribution, Transport, and Issuing of Blood and Blood Components: The Example of Greece, 52\u003cbr\u003e \u003ci\u003eConstantina Politis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7 Medical Decision, Ordering, Administration of Component, and Monitoring of the Patient, 61\u003cbr\u003e \u003ci\u003eMickey B.C. Koh, Ramir Alcantara, Mark Grumbridge, and Ai Leen Ang\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eSection 2.2: How the System Works\u003c\/p\u003e \u003cp\u003e8 Blood Donation: An Approach to Donor Vigilance, 77\u003cbr\u003e \u003ci\u003ePeter Tomasulo, Madhav Erraguntla, and Hany Kamel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 Preparation of Blood Components, 99\u003cbr\u003e \u003ci\u003eErhard Seifried, Reinhard Henschler, Juergen Luhm, Thea Mueller-Kuller, Hans-Ulrich Pfeiffer, Walid Sireis, and Markus M. Mueller\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10 Testing, Issuing, and Transport of Blood Components, 113\u003cbr\u003e \u003ci\u003eConstantina Politis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 Clinical Activities: Medical Decision-making, Sampling, Ordering Components, Administration, and Patient Monitoring, 126\u003cbr\u003e \u003ci\u003eClare Taylor\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 3 National or Regional Hemovigilance Systems\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e12 The French Hemovigilance Network: From the Blood Scandal to Epidemiologic Surveillance of the Transfusion Chain, 147\u003cbr\u003e \u003ci\u003ePhilippe Renaudier\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 The Japanese Hemovigilance System, 159\u003cbr\u003e \u003ci\u003eHitoshi Okazaki, Naoko Goto, Shun-ya Momose, Satoru Hino, and Kenji Tadokoro\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14 Setting up a National Hemovigilance System: SHOT, 168\u003cbr\u003e \u003ci\u003eHannah Cohen and Lorna M. Williamson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 The Dutch Hemovigilance System: Transfusion Reactions in Patients (TRIP), 180\u003cbr\u003e \u003ci\u003eMartin R. Schipperus, Johanna Wiersum-Osselton, Pauline Y. Zijlker-Jansen, and Anita J.W. van Tilborgh-de Jong\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16 Regulatory, Public Health, and International Aspects of Hemovigilance in Canada, 191\u003cbr\u003e \u003ci\u003ePeter R. Ganz and Jun Wu\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 Setting up and Implementation of the National Hemovigilance System in Italy, 204\u003cbr\u003e \u003ci\u003eGiuliano Grazzini and Simonetta Pupella\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18 The Australian Hemovigilance System, 209\u003cbr\u003e \u003ci\u003eErica M. Wood, Lisa J. Stevenson, Simon A. Brown, and Christopher J. Hogan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19 Biovigilance in the United States, 220\u003cbr\u003e \u003ci\u003eD. Michael Strong, Barbee Whitaker, Matthew J. Kuehnert, and Jerry A. Holmberg\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20 Arab Hemovigilance Network, 226\u003cbr\u003e \u003ci\u003eSalwa Hindawi, Magdy Elekiaby, and Gamal Gabra\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 4 Hemovigilance at the International Level\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e21 Hemovigilance in the European Community, 235\u003cbr\u003e \u003ci\u003eJean-Claude Faber\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22 International collaboration, 253\u003cbr\u003e \u003ci\u003ePaul F.W. Strengers\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23 Hemovigilance in Developing Countries, 260\u003cbr\u003e \u003ci\u003eJean-Claude Faber\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 5 Achievements\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e24 Achievements Through Hemovigilance, 281\u003cbr\u003e \u003ci\u003eJean-Claude Faber and F´atima Nascimento\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 6 Developments\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e25 Vigilance of Alternatives for Blood Components, 305\u003cbr\u003e \u003ci\u003eDafydd Thomas\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26 Surveillance of Clinical Effectiveness of Transfusion, 322\u003cbr\u003e \u003ci\u003eBrian McClelland and Katherine Forrester\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e27 Biovigilance, 326\u003cbr\u003e \u003ci\u003eJerry A. Holmberg, Matthew J. Kuehnert, and D. Michael Strong\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eAppendices\u003c\/p\u003e \u003cp\u003eAppendix A Glossary, 343\u003c\/p\u003e \u003cp\u003eAppendix B Proposed standard definitions for surveillance of non infectious adverse transfusion reactions, 351\u003c\/p\u003e \u003cp\u003eAppendix C Standard for surveillance of complications related to blood donation, 360\u003c\/p\u003e \u003cp\u003eIndex, 369\u003c\/p\u003e","brand":"John Wiley and Sons Ltd","offers":[{"title":"Default Title","offer_id":49402387431767,"sku":"9780470655276","price":111.56,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780470655276.jpg?v=1730480245","url":"https:\/\/bookcurl.com\/products\/hemovigilance-9780470655276","provider":"Book Curl","version":"1.0","type":"link"}